


**Product Name** : XRD-0394  
**Cat. No.** : PC-22113  
**CAS No.** : 2595308-10-2  
**Molecular Formula** : C<sub>26</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>4</sub>S  
**Molecular Weight** : 527.62  
**Target** : ATM/ATR  
**Solubility** : 10 mM in DMSO



CAS: 2595308-10-2

### Biological Activity

XRD-0394 (XRD0394) is a potent, specific, orally bioavailable dual inhibitor of DNA damage-response kinases **ATM** and **DNA-PK** with IC<sub>50</sub> of 0.39 and 0.89 nM, respectively.

XRD-0394 is >100-fold selective for ATM and DNA-PK versus mTOR, PI3K $\beta$ , ATR and SMG-1 and > 40-fold selective versus PI3K $\gamma$  and PI3K $\delta$ , and 14-fold selective versus PI3K $\alpha$ .

XRD-0394 inhibits phosphorylation by ATM and DNA-PK kinases, but not structurally related kinases, in human tumor cell.

XRD-0394 shows both significantly greater radiosensitization and less cellular toxicity in the absence of IR when compared to a specific ATR inhibitor, RP3500.

XRD-0394 also potentiates the effectiveness of topoisomerase I inhibitors in vitro.

XRD-0394 shows single agent activity and synergy in combination with PARP inhibitors in cells lacking BRCA1/2.

### References

Gilmer TM, et al. *Mol Cancer Ther.* 2024 Apr 8. doi: 10.1158/1535-7163.MCT-23-0890.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com